Sequenta, Inc.'s ClonoSIGHT MRD Test Can Detect Relapse Of Diffuse Large B-Cell Lymphoma More Than Seven Months Before CT Scan

Published: Dec 09, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW ORLEANS--(BUSINESS WIRE)--Sequenta, Inc. today announced that researchers from the National Cancer Institute (NCI) will present data showing that in the first five years post-treatment, the company’s sequencing-based minimal residual disease (MRD) assay can detect relapse of diffuse large B-cell lymphoma (DLBCL) a median of 7.4 months prior to when the disease is detected via CT scan. Sequenta’s recent announcement of the commercial launch of the ClonoSIGHT test for use in DLBCL patients is based on this clinical validation data, which will be presented at the 55th annual meeting of the American Society of Hematology (ASH).

Help employers find you! Check out all the jobs and post your resume.

Back to news